Supplementary Figure 2.
Sanger sequencing from multiple germline tissue t pes in one patient. atient N244 had both a buccal s ab and an immortali ed cell line a ailable for anal sis. Sequencing of the buccal s ab implied germline inheritence of the RRAS2 p. 2L mutations. o e er, Sanger sequencing of the cells re ealed a ild t pe sequence indicating the buccal sample as contaminated ith tumor and the mutation as in fact somatic in origin. Figure . andscape plot of mutations detected from exome and targeted resequencing. enes are plotted on the -axis with all 1 0 patients from the combined cohorts on the -axis. All pathogenic mutations listed in supplemental tables 2 and 3 are depicted as a vertical bars. Mutations detected at diagnosis are in black and mutations only detected at relapse are in red. As noted in supplemental tables 2 and 3, mutations detected at diagnosis were present at relapse. Figure . Segmented allelic cop number heat map. Amplifications are depicted in red, deletions in blue and cop neutral loss of hetero gosit in green.
Supplementary
onosom , cop neutral loss of q and q are the onl recurring structural alterations.
Supplementary Figure . llustrati e e amples sho ing cop ratio and allelic balance in genomes ith recurrent structural alterations. atient N 2 had monosom at diagnosis sho n b matched lo er cop ratio and allelic imbalance at chromosome . atient N 24 had cnL at chromosome here resides. his patient as born ith a hetero gous mutation that under ent uniparental isodisom .
a b
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Supplementary Figure . enome wide DNA methylation analysis in patients with AS mutations. our subjects with AS mutations (red) and appropriate controls (green) were analyzed on the Illumina 4 k Bead Chip platform. One patient with a A mutation (blue) was included for comparison. or each mutation e used A S L to computationally estimate the fraction of cancer cells or cancer cell fraction (CCF) that harbor a given somatic variant. Shown are the CCFs for each somatic variant in both respective samples with diagnosis on the left and relapse on the right. The CCF for all putative driver events detected approach 100% at relapse, implying that these mutations are present in the same dominant clone. atient N had t o cop number e ents, one cnL at diagnosis and one unbalanced amplification deletion at relapse.
Supplementary Figure 9.
Single colony analysis demonstrated progression of disease in UPN1420. (A) At diagnosis of JMML, UPN1420 possessed compound heterozygous mutations in NF1 as well as ASXL1 in all six single colonies analyzed. Upon transformation to AML, the patient acquired compound heterozygous mutations in SH2B3 as detected in unsorted mononuclear cells. Analysis of single colonies at relapse demonstrated three patterns: (1) colonies with heterozygous SH2B3 lesions, (2) colonies homozygous for SH2B3 p.Q258* mutation and (3) colonies homozygous for SH2B3 p.F390fs mutation. The colony containing compound heterozygous mutations was therefore first to arise. (B) Copy number data comparing the diagnostic and relapsed timepoints established that a copy number alteration led to two distinct clones arising with colonies homozygous for each of the respective SH2B3 lesions. . EFS is displayed for all 27 patients in the exome cohort (two patients with Noonan's syndrome were excluded) EFS is displayed for 71 distinct patients from our validation cohort. ry 11. Overall Survival (OS) based on canonical mutation. Individual canonical driver mutations were not associated with outcome (Log-rank p=0.834).
Supplementary Figure 12.
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